Benzinga··PrnewswireGalmed Files 2025 Annual Report as Aramchol Advances Through Clinical Pipeline
Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.
GLMDFDA approvalclinical trials